Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice.

Biochemical Institute, University of Kiel, Kiel, Germany.
Human Molecular Genetics (Impact Factor: 6.68). 09/2008; 17(22):3437-45. DOI: 10.1093/hmg/ddn237
Source: PubMed

ABSTRACT Despite the progress in the treatment of lysosomal storage disorders (LSDs) mainly by enzyme replacement therapy, only limited success was reported in targeting the appropriate lysosomal enzyme into the brain. This prevents efficient clearance of neuronal storage, which is present in many of these disorders including alpha-mannosidosis. Here we show that the neuropathology of a mouse model for alpha-mannosidosis can be efficiently treated using recombinant human alpha-mannosidase (rhLAMAN). After intravenous administration of different doses (25-500 U/kg), rhLAMAN was widely distributed among tissues, and immunohistochemistry revealed lysosomal delivery of the injected enzyme. Whereas low doses (25 U/kg) led to a significant clearance (<70%) in visceral tissues, higher doses were needed for a clear effect in central and peripheral nervous tissues. A distinct reduction (<50%) of brain storage required repeated high-dose injections (500 U/kg), whereas lower doses (250 U/kg) were sufficient for clearance of stored substrates in peripheral neurons of the trigeminal ganglion. Successful transfer across the blood-brain barrier was evident as the injected enzyme was found in hippocampal neurons, leading to a nearly complete disappearance of storage vacuoles. Importantly, the decrease in neuronal storage in the brain correlated with an improvement of the neuromotor disabilities found in untreated alpha-mannosidosis mice. Uptake of rhLAMAN seems to be independent of mannose-6-phosphate receptors, which is consistent with the low phosphorylation profile of the enzyme. These data suggest that high-dose injections of low phosphorylated enzymes might be an interesting option to efficiently treat LSDs with CNS involvement.

Download full-text


Available from: Judith Blanz, Jul 03, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Here we hypothesized that the water-soluble lysosomal enzymes may cross the blood-brain-barrier and reach the brain using the mechanism of unspecific fluid-phase endocytosis. We also highlight studies that show that, at higher serum concentrations, a fraction of these proteins can reach the brain after intravenous injection, and we suggest some experiments to study this hypothesis. Finally we discuss the implications of this for treatments such as enzyme replacement of lysosomal storage disorders.
    Medical Hypotheses 02/2014; 82(4). DOI:10.1016/j.mehy.2014.01.029 · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Developing therapies for the brain is perhaps the greatest challenge facing modern medicine today. While a great many potential therapies show promise in animal models, precious few make it to approval or are even studied in human patients. The particular challenges to the translation of neurotherapeutics to the clinic are many, but a major barrier is difficulty in delivering therapeutics into the brain. The goal of this workshop was to present ways to deliver therapeutics to the brain, including the limitations of each method, and describe ways to track their delivery, safety, and efficacy. Solving the problem of delivery will aid translation of therapeutics for patients suffering from neurodegeneration and other disorders of the brain.
    06/2012; 2(3). DOI:10.1007/s13346-012-0068-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: Industry has become aware of the problem of severe generator damage due to stator ground faults. It has been suggested that, to prevent this damage, the practices employed for neutral grounding should be changed. This paper provides an analytical perspective on this problem and suggests that the real issue is the manner in which the neutral of the generator itself is grounded
    IEEE Transactions on Industry Applications 10/1998; DOI:10.1109/28.720430 · 2.05 Impact Factor